EVe Mobility Acquisition Corp (EVE)

Joby Aviation (JOBY) shares dropped about 7% on Tuesday morning after U.S. inflation data tempered hopes for near-term rate cuts. The slide hit other air-taxi n

EVE (NYSE: EVEX - Get Free Report) is expected to release its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect EVE to post earnings of ($0.16) per share for the quarter. Individuals may review the information on the company's upcoming Q3 2025 earningreport for the latest details on the call scheduled

I rate EVEX a buy, targeting $10.4 by 2030 as the company de-risks and approaches production milestones. EVE's competitive edge stems from Embraer's aerospace expertise, robust design, and a $14bn pre-order book, despite the high-risk eVTOL sector. Financial estimates assume half of pre-orders convert, with profitability expected after scaling production post-2029.

SANTA MONICA, CA, Oct. 21, 2024 (GLOBE NEWSWIRE) -- EVe Mobility Acquisition Corp (NYSE American: EVE), a Cayman Islands exempted company (“EVe” or the “Company”), announced today that on October 16, 2024, the Company received a written late extension request acceptance letter from the NYSE American LLC (“NYSE American” or the “NYSE Regulation”), because it is not in compliance with the continued listing standards of the NYSE American. Specifically, the Company has not met the requirements set forth in Sections 134 and 1101 of the NYSE American Company Guide due to its delayed filings of the Form 10-K for the year ended December 31, 2023, and its Form 10-Qs for the periods ended March 31, 2024, and June 30, 2024 (the “Delayed Filings”).

In the context of the U.S. stock market, flying cars at this point primarily refer to electric vertical takeoff and landing aircraft or eVTOLS. As the name implies, eVTOLs are electric-powered aircraft “that take off and land going straight up and down.

SANTA MONICA, CA, May 13, 2024 (GLOBE NEWSWIRE) -- EVe Mobility Acquisition Corp (“EVe”) (NYSE American: EVE), a special purpose acquisition company, announced today that on May 13, 2024, its board of directors (the “Board”) decided to extend the date by which EVe must consummate an initial business combination from May 17, 2024 to June 17, 2024 (the “Sixth Optional Extension”). This is the sixth of up to six one-month extensions available to EVe pursuant to its amended and restated memorandum and articles of association.

SANTA MONICA, CA, April 19, 2024 (GLOBE NEWSWIRE) -- EVe Mobility Acquisition Corp (the “Company”) (NYSE American: EVE), a special purpose acquisition company, announced today that the Company has received notice from NYSE Regulation (the “NYSE Notice”), stating that the Company is not in compliance with the continued listing standards of the NYSE American LLC (the “Exchange”) under the timely filing criteria included in Section 1007 of the NYSE American Company Guide (the “Company Guide”) because the Company failed to timely file its Annual Report on Form 10-K for the year ended December 31, 2023 (the “Delinquent Report”), which was due to be filed with the Securities and Exchange Commission (the “SEC”) no later than April 16, 2024 (the “Filing Delinquency”).

SANTA MONICA, CA, April 12, 2024 (GLOBE NEWSWIRE) -- EVe Mobility Acquisition Corp (“EVe”) (NYSE American: EVE), a special purpose acquisition company, announced today that on April 12, 2024, its board of directors (the “Board”) decided to extend the date by which EVe must consummate an initial business combination from April 17, 2024 to May 17, 2024 (the “Fifth Optional Extension”). This is the fifth of up to six one-month extensions available to EVe pursuant to its amended and restated memorandum and articles of association.

All of the ingredients appear to be in place to make electric vertical take-off and landing, or eVTOL, aircraft very successful. These vehicles, also known as flying cars, will be a quicker, more economical way to move passengers around cities.

SANTA MONICA, CA, March 14, 2024 (GLOBE NEWSWIRE) -- EVe Mobility Acquisition Corp (“EVe”) (NYSE American: EVE), a special purpose acquisition company, announced today that on March 14, 2024, its board of directors (the “Board”) decided to extend the date by which EVe must consummate an initial business combination from March 17, 2024 to April 17, 2024 (the “Fourth Optional Extension”). This is the fourth of up to six one-month extensions available to EVe pursuant to its amended and restated memorandum and articles of association.

SANTA MONICA, CA, Feb. 14, 2024 (GLOBE NEWSWIRE) -- EVe Mobility Acquisition Corp (“EVe”) (NYSE American: EVE), a special purpose acquisition company, announced today that on February 14, 2024, its board of directors (the “Board”) decided to extend the date by which EVe must consummate an initial business combination from February 17, 2024 to March 17, 2024 (the “Third Optional Extension”). This is the third of up to six one-month extensions available to EVe pursuant to its amended and restated memorandum and articles of association.

SANTA MONICA, CA, Jan. 15, 2024 (GLOBE NEWSWIRE) -- EVe Mobility Acquisition Corp (“EVe”) (NYSE American: EVE), a special purpose acquisition company, announced today that on January 12, 2024, its board of directors (the “Board”) decided to extend the date by which EVe must consummate an initial business combination from January 17, 2024 to February 17, 2024 (the “Second Optional Extension”). This is the second of up to six one-month extensions available to EVe pursuant to its amended and restated memorandum and articles of association.

Given flying cars' ability to ferry passengers to different locations within cities quite cheaply, I've long believed that the demand for flying cars will eventually go through the roof (no pun intended). While researching this article, I found that many researchers have reached the same conclusion about flying cars, also called eVTOLs.

China's EVE Energy Co Ltd will supply BMW with large cylindrical batteries for its electric cars in Europe, two people with knowledge of the matter said, as the German automaker follows Tesla Inc in adopting the new technology.

REINACH, Switzerland--(BUSINESS WIRE)--Evolva (SIX:EVE) today announced the receipt of a letter from the US Environmental Protection Agency (EPA) shortly ahead of the expected regulatory registration. In the course of its in-depth review of Evolva’s application to register nootkatone as a “manufacturing-use product” (MP), the Agency identified one study for which it could not complete its review and has requested further information. Evolva is in close interaction with EPA to resolve the identified issue and to determine the next steps which will include extension of the regulatory deadline. Evolva will inform its stakeholders accordingly as soon as it will have gained more visibility. Evolva remains fully committed to the project and is confident that nootkatone will be registered as an active ingredient against ticks and mosquitoes. About nootkatone Nootkatone is an ingredient found in minute quantities in the bark of the Alaska yellow cedar (also known as the Nootka cypress) and in the skin of grapefruit. Nootkatone has a long history as an approved flavor and fragrance. It can also be produced on an industrial scale from brewing via yeast fermentation. Nootkatone has been tested against a variety of biting arthropods, including the ticks that are responsible for spreading Lyme disease and the mosquitoes that spread like Zika, chikungunya, dengue and West Nile viruses. About Evolva’s collaboration with CDC and BARDA This project has been funded with Federal funds from the Centers for Disease Control and Prevention (CDC), and managed by the Office of the Assistant Secretary for Preparedness and Response (ASPR), Biomedical Advanced Research and Development Authority (BARDA), under Contract No. HHSO100201700015C. About Lyme disease and Zika virus Lyme disease is caused by the bacterium Borrelia burgdorferi and is transmitted to humans through the bite of infected blacklegged ticks (aka deer tick, Ixodes scapularis and Ixodes pacificus). Zika virus is spread to people primarily through the bite of an infected Aedes species mosquito (Ae. aegypti and Ae. albopictus). There is no vaccine or medicine for Zika; the best protection is to avoid mosquito bites. About tick- and mosquito-borne illnesses in the US Last year, the CDC issued a report stating that illnesses from mosquito, tick and flea bites tripled from 2004-2016. The report warned that better options are needed in the fight against these disease vectors. "Widespread and difficult to control diseases from mosquito, tick, and flea bites are major causes of sickness and death worldwide. The growing number and spread of these diseases pose an increasing risk in the U.S." The report found that the nation needs to be better prepared to face this public health threat. About Evolva Evolva solves the supply chain issues of nature through a 21st century mix of biotechnology and fermentation. We develop, make and sell ingredients that provide significant health, wellness and nutrition benefits to people in their daily life, but whose supply chain issues have limited their use until now. Our flagship ingredients are stevia, nootkatone and resveratrol. To make our world sustainable requires nature and technology to work together as one, and our aim is to play a (small) part in achieving this transformation. For more information see https://www.evolva.com. This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. There can be no guarantee that Nootkatone will be registered as a manufacturing-use product (MP). Nor can there be any guarantee that Nootkatone as MP (which is intended for formulation in end-use products (EPs)) will be commercially successful in the future. In particular, management’s expectations regarding Nootkatone could be affected by, among other things, the uncertainties inherent in research and development, including unexpected trial results and/or any other unexpected deficiencies EPA may still identify in the course of its continued review of the application. Against the background of these uncertainties, readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.